hematologynews.net

Hematology Xagena News

High-risk acute myelogenous leukemia: maintenance therapy with Azacitadine and Valproic acid after allogeneic stem cell transplant. Relapse is the major cause of failure after allogeneic stem cell transplantation ( Allo-SCT ) for acute myelogenous leukemia ( AML ). Allo-SCT for high risk acute myelogenous leukemia, defined by . Relapsed B-cell acute lymphoblastic leukemia: durability of CAR T-cell therapy response may depend on pretreatment disease burden. Pembrolizumab in combination with Pomalidomide a...

http://www.hematologynews.net/

OVERVIEW OF hematologynews.net

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

15

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR HEMATOLOGYNEWS.NET

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

June

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.6 out of 5 with 9 reviews

5 star

8

4 star

0

3 star

0

2 star

0

1 star

1

Hey there! Start your review of hematologynews.net

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

1.9 seconds

FAVICON PREVIEW

16x16
32x32
64x64
128x128
160x160
192x192
256x256

CONTACTS AT HEMATOLOGYNEWS.NET

XAGENA DI CARLO FRANZINI

via Q●●●●●nno 9

Mi●●no , 20122

IT

View this contact

Carlo Franzini

Carlo Franzini

via Q●●●●●nno 9

Mi●●no , 20122

IT

39 02●●●●●30029

39 02●●●●●33168

ma●●●●●●●@xagena.it

View this contact

Register.it S.p.A.

Register.it S.p.A.

Via Mo●●●●●●ri s/n

Be●●mo , 24126

IT

39 03●●●●●30400

39 03●●●●●30312

su●●●●●@register.it

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2005 February 23
UPDATED: 2014 March 20
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

19

YEARS
2

MONTHS
8

DAYS

NAME SERVERS

1: ns1.register.it
2: ns2.register.it

REGISTRAR

REGISTER.IT SPA

WHOIS : whois.register.it

REFERRED : http://we.register.it

CONTENT

PAGES IN
THIS WEBSITE

15

SSL

EXTERNAL LINKS

523

SITE IP

151.236.59.184

LOAD TIME

1.918 sec

SCORE

6.2

PAGE TITLE

Hematology Xagena News | hematologynews.net Reviews

<META> DESCRIPTION

High-risk acute myelogenous leukemia: maintenance therapy with Azacitadine and Valproic acid after allogeneic stem cell transplant. Relapse is the major cause of failure after allogeneic stem cell transplantation ( Allo-SCT ) for acute myelogenous leukemia ( AML ). Allo-SCT for high risk acute myelogenous leukemia, defined by . Relapsed B-cell acute lymphoblastic leukemia: durability of CAR T-cell therapy response may depend on pretreatment disease burden. Pembrolizumab in combination with Pomalidomide a...

<META> KEYWORDS

1 toggle navigation

2 mappa

3 xagena

4 chi siamo

5 news it

6 news en

7 medicinanews

8 medicinenews

9 partner

10 cardiologia

CONTENT

Page content here

KEYWORDS ON PAGE

toggle navigation,mappa,xagena,chi siamo,news it,news en,medicinanews,medicinenews,partner,cardiologia,news,farmaci,focus,oncologia,immunoterapia,oncohub,oncodermatologia,oncoematologia,oncogastroenterologia,oncogeriatria,oncoginecologia,onconeurologia

SERVER

nginx

POWERED BY

PleskLin

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Hematology Xagena News | hematologynews.net Reviews

https://hematologynews.net

High-risk acute myelogenous leukemia: maintenance therapy with Azacitadine and Valproic acid after allogeneic stem cell transplant. Relapse is the major cause of failure after allogeneic stem cell transplantation ( Allo-SCT ) for acute myelogenous leukemia ( AML ). Allo-SCT for high risk acute myelogenous leukemia, defined by . Relapsed B-cell acute lymphoblastic leukemia: durability of CAR T-cell therapy response may depend on pretreatment disease burden. Pembrolizumab in combination with Pomalidomide a...

INTERNAL PAGES

hematologynews.net

1

Apixaban for the treatment of deep vein thrombosis and pulmonary embolism, and for the reduction in the risk of recurrent DVT and PE following initial therapy | Hematology Xagena

https://www.hematologynews.net/articolo/apixaban-for-the-treatment-of-deep-vein-thrombosis-and-pulmonary-embolism-and-for-the-reduction-in-the-risk-of-recurrent-dvt-and-pe-following-initial-therapy

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Apixaban for the treatment of deep vein thrombosis and pulmonary embolism, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Once a VTE has occurred, approximately 33% of patients are at risk of a recurrence within 10 years. The FDA approval of Eliquis for the treatment of deep vein thr...

2

Leukemias with ALK mutations, role of ALK inhibitors | Hematology Xagena

https://www.hematologynews.net/articolo/leukemias-with-alk-mutations-role-of-alk-inhibitors

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Leukemias with ALK mutations, role of ALK inhibitors. Genetic lesions involving ALK have been seen recurrently in a number of different types of solid tumors, but ALK mutations have not previously been implicated as a major contributor to leukemia. To assess whether the two mutations identified had the potential to make ...

3

Pomalidomide plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma | Hematology Xagena

https://www.hematologynews.net/articolo/pomalidomide-plus-low-dose-dexamethasone-in-patients-with-relapsed-and-refractory-multiple-myeloma

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Pomalidomide plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma. In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed Lenalidomide and Bortezomib had been enrolled at the time of the data cutoff. The most frequent grade 3-4 adverse ev...

4

Eloctate for haemophilia A: twice-weekly prophylactic dosing maintained low bleeding rates in children under age 12 | Hematology Xagena

https://www.hematologynews.net/articolo/eloctate-for-haemophilia-a-twice-weekly-prophylactic-dosing-maintained-low-bleeding-rates-in-children-under-age-12

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Eloctate for haemophilia A: twice-weekly prophylactic dosing maintained low bleeding rates in children under age 12. Eloctate was generally well-tolerated and no inhibitors ( neutralising antibodies that may interfere with the activity of the therapy ) were detected. The primary endpoint of the study was to evaluate the ...

5

Blincyto, the first-and-only bispecific CD19-directed CD3 T-cell engager immunotherapy for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia | Hematology Xagena

https://www.hematologynews.net/articolo/blincyto-the-first-and-only-bispecific-cd19-directed-cd3-t-cell-engager-immunotherapy-for-the-treatment-of-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Blincyto, the first-and-only bispecific CD19-directed CD3 T-cell engager immunotherapy for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval. Relapsed or refractory was defined as relapsed with first remission duration of greater ...

UPGRADE TO PREMIUM TO VIEW 10 MORE

TOTAL PAGES IN THIS WEBSITE

15

LINKS TO THIS WEBSITE

stemtherapynews.net

Muscle stem cell therapy: Forskolin increases the numbers of muscle stem cells in lab | Stem cell therapy Xagena

http://www.stemtherapynews.net/articolo/muscle-stem-cell-therapy-forskolin-increases-the-numbers-of-muscle-stem-cells-in-lab

Stem cell therapy Xagena. Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Muscle stem cell therapy: Forskolin increases the numbers of muscle stem cells in lab. Zon shared his results with Amy Wagers at Harvard Department of Stem Cell and Regenerative Biology, who tested the six chemicals in mice. One of the six, called Forskolin, was found to increase the numbers...

stemtherapynews.net

Stem cell therapy for rheumatoid arthritis | Stem cell therapy Xagena

http://www.stemtherapynews.net/articolo/stem-cell-therapy-for-rheumatoid-arthritis

Stem cell therapy Xagena. Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Stem cell therapy for rheumatoid arthritis. Rheumatoid arthritis is the most common inflammatory arthritis, affecting 0.5% to 1% of the general population worldwide. MSCs have been shown to exert immunomodulating properties and to regulate the function of a broad number of immune cells including...

stemtherapynews.net

Stem cell therapy to prevent myocardial infarctions | Stem cell therapy Xagena

http://www.stemtherapynews.net/articolo/stem-cell-therapy-to-prevent-myocardial-infarctions

Stem cell therapy Xagena. Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Stem cell therapy to prevent myocardial infarctions. The use of stem cell therapy to prevent myocardial infarctions is explored in a Comment published in The Lancet. Autologous cells are sourced from the patient they are used to treat. LVEF increased slightly in the placebo group ( 47% to 50% ) ...

stemtherapynews.net

Stem cell therapy Xagena News

http://www.stemtherapynews.net/news

Stem cell therapy Xagena. Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Heart failure: allogeneic mesenchymal stem cells restore endothelial function by stimulating endothelial progenitor cells. Ischemic cardiomyopathy: transendocardial mesenchymal stem cells and mononuclear bone marrow cells appears to be safe. Researchers at Gladstone Institutes have developed a t...

stemtherapynews.net

Stem cell gene therapy for sickle cell disease advances toward clinical trials | Stem cell therapy Xagena

http://www.stemtherapynews.net/articolo/stem-cell-gene-therapy-for-sickle-cell-disease-advances-toward-clinical-trials

Stem cell therapy Xagena. Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Stem cell gene therapy for sickle cell disease advances toward clinical trials. Sickle cell disease causes the body to produce red blood cells that are formed like the crescent-shaped blade of a sickle, which hinders blood flow in the blood vessels and deprives the body's organs of oxygen. The r...

stemtherapynews.net

Ataxia telangiectasia: a brain and spinal cancer following human fetal stem cell therapy | Stem cell therapy Xagena

http://www.stemtherapynews.net/articolo/ataxia-telangiectasia-a-brain-and-spinal-cancer-following-human-fetal-stem-cell-therapy

Stem cell therapy Xagena. Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Ataxia telangiectasia: a brain and spinal cancer following human fetal stem cell therapy. A case report published in the journal, PLoS Medicine, describes a rare side effect of human fetal stem cell therapy. The researchers speculate that the patient's underlying condition may itself have allowe...

vaccinesnews.net

Protection against varicella with two doses of combined MMRV vaccine versus one dose of monovalent varicella vaccine | Vaccines Xagena

http://www.vaccinesnews.net/articolo/protection-against-varicella-with-two-doses-of-combined-mmrv-vaccine-versus-one-dose-of-monovalent-varicella-vaccine

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Protection against varicella with two doses of combined MMRV vaccine versus one dose of monovalent varicella vaccine. Participants and their parents or guardians, individuals involved in assessment of any outcome, and sponsor staff involved in review or analysis of data were masked to treatment assignment. The primary ef...

vaccinesnews.net

Intussusception risk after rotavirus vaccination: potential risk with RotaTeq and Rotarix | Vaccines Xagena

http://www.vaccinesnews.net/articolo/intussusception-risk-after-rotavirus-vaccination-potential-risk-with-rotateq-and-rotarix

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Intussusception risk after rotavirus vaccination: potential risk with RotaTeq and Rotarix. Researchers have studied this association among infants in the United States. Potential cases of intussusception and vaccine exposures from 2004 through mid-2011 were identified through procedural and diagnostic codes. The statisti...

infectivology.net

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression | Infectivology Xagena

http://infectivology.net/articolo/interleukin-6-and-d-dimer-levels-at-seroconversion-as-predictors-of-hiv-1-disease-progression

Banca dati di FarmacoVigilanza. Banca dati per una ricerca mirata in Medicina. Indice analitico in Medicina. Banca dati sui Farmaci. Banca dati di Medicina. Banca dati di news Headlines. Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. SPARTAC was a randomized controlled trial comparing three strategies of intervention in primary HIV-1 infection [ no therapy, 12-week or 48-week antiretroviral therapy ( ART ) ]. For the 73 participants not initiating ART ( med...

UPGRADE TO PREMIUM TO VIEW 514 MORE

TOTAL LINKS TO THIS WEBSITE

523

OTHER SITES

hematologylinks.info

hematologylinks.info Linkcollection

hematologymarketinsights.blogspot.com

Hematology Competitive Insights

Monday, August 24, 2009. Resumption after an extended hiatus. Things have been really insanely busy on the work front over the last year, necessitating some radical prioritisation and thus I have only posted on Pharma Strategy Blog. Instead of here and Oncology Market Trends. It will be changing from this week as things gear up for some interesting new perspectives on the Pharma CI front and I'd like to take the time to thank everyone for their patience during the hiatus. Monday, November 3, 2008. The st...

hematologymastoid.blogspot.com

Hematology Mastoid

Tuesday, March 2, 2010. During my stay for at least twice per year to pursue. During the Pioneers in Hematology is the advantage of cord blood over bone marrow slides under the microscope, interpreting various haematological test results. Professor Diamond begins this lecture with the nose, paying particular attention to the recently published Handbook of Transfusion Medicine, the Handbook of Transfusion Medicine, the Handbook of Transfusion. Subscribe to: Posts (Atom). View my complete profile.

hematologynet.eu

H-Net - Hematology Network

This unique Internet platform, which is a product of the H-net project, is a knowledge network specifically designed for clinicians, laboratory technicians and other professionals active in the specialty of hematology. The Hematology Confolio Network is a knowledge network of electronic repositories (e-portfolios) on the internet where you can easily search for learning resources related to hematology, upload your own resources and link to those of others. H-Net adopts the Brussels Declaration.

hematologynews.com

Home : Hematology News

From Oncology Practice powered by:. Lymph2Cx assay identifies outcomes in DLBCL. Pretransplant support helps cancer patients sleep better. Esophagogastric cancer chemotherapy commonly causes VTE. This week's quiz is on. Guideline updates for non-Hodgkin lymphomas: Part 3. Become a fan on Facebook. Follow Us on Twitter. Subscribe to our RSS Feed. Lymph2Cx assay identifies outcomes in DLBCL. Treatment of choice for NLPHL? Eltrombopag yields 40% response rate in pediatric immune thrombocytopenia. Treatment ...

hematologynews.net

Hematology Xagena News

High-risk acute myelogenous leukemia: maintenance therapy with Azacitadine and Valproic acid after allogeneic stem cell transplant. Relapse is the major cause of failure after allogeneic stem cell transplantation ( Allo-SCT ) for acute myelogenous leukemia ( AML ). Allo-SCT for high risk acute myelogenous leukemia, defined by . Relapsed B-cell acute lymphoblastic leukemia: durability of CAR T-cell therapy response may depend on pretreatment disease burden. Pembrolizumab in combination with Pomalidomide a...

hematologynotes.com

IIS7

hematologynotes.info

IIS7

hematologynursejobs.com

Hematologynurse Jobs - HematologynurseJobs.com

Get Jobs by Email. Travel - (Peds Hem/Onc/Bmt RN). Posted Date: 8 days ago. Date ASAP Pay Rate $31.00 - $33.00 Job Description and Requirements Pediatric Hematology. Travel - (Peds Hem/Onc/Bmt RN) This Pedi. Navigator - Registered Nurse. Posted Date: 1 days ago. Navigator - Registered Nurse. RN We have an exceptional opportunity for a Registered Nurse. In the Medford area. This. Posted Date: 17 days ago. Oncology RN Registered Nurse. Assignment. As Pediatric. Posted Date: 1 days ago. Health System, has a...

hematologyoc.com

PlaceHolder for hematologyoc.com

This is the placeholder for domain hematologyoc.com. If you see this page after uploading site content you probably have not replaced the index.html file. This page has been automatically generated by Plesk.

hematologyoncology-iq.com

HematologyOncology-IQ

Med-IQ - Inspiring Medical Education. Med-IQ CME / CE News. How Do We Do It. There is no activity or activities listed. If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual. Bookmark These Med-IQ Sites. Attend a free CME/CE meeting in your area learn more about Med-IQ’s current events. Be sure to check back frequently for updates!